A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 2, 2016, Pages 519-527

  Dowall, S D ^a   Buttigieg, K R ^a   Findlay Wilson, S J D ^a   Rayner, E ^a   Pearson, G ^a   Miloszewska, A ^a   Graham, V A ^a   Carroll, M W ^a   Hewson, R ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Crimean Congo hemorrhagic fever, nucleoprotein, protection, vaccine

Indexed keywords

GAMMA INTERFERON RECEPTOR 1; POXVIRUS VECTOR; RECOMBINANT NUCLEOPROTEIN VACCINE; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS VACCINE; ALPHA BETA INTERFERON RECEPTOR; NUCLEOPROTEIN; RECOMBINANT VACCINE; VIRAL PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY INFILTRATE; LETHAL DOSE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; SURVIVAL; VACCINE FAILURE; VACCINIA VIRUS; VIRUS LOAD; WESTERN BLOTTING; ANIMAL; BLOOD; CELL LINE; CHICK EMBRYO; CHLOROCEBUS AETHIOPS; GENETICS; HAMSTER; HEMORRHAGIC FEVER, CRIMEAN; HUMAN; IMMUNIZATION; IMMUNOLOGY; KNOCKOUT MOUSE; NAIROVIRUS; VACCINE IMMUNOGENICITY; VERO CELL LINE;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; CRICETINAE; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; IMMUNIZATION; IMMUNOGENICITY, VACCINE; MICE; MICE, KNOCKOUT; NUCLEOPROTEINS; RECEPTOR, INTERFERON ALPHA-BETA; VACCINES, SYNTHETIC; VERO CELLS; VIRAL LOAD; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84960968526     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1078045     Document Type: Article

References (67)

1. WHO, Crimean-Congo haemorrhagic fever. Factsheet No208, 2013; http://www.who.int/mediacentre/fact sheets/fs208/en/
2. O.Ergonul Crimean-Congo haemorrhagic fever. Lancet Infect Dis, 2006; 6(4): p:203-14; PMID:16554245; http://dx.doi.org/10.1016/S1473-3099(06)70435-2
3. Watts DM, Kziasek TG, Linthicum KJ, Hoogstraal H.Crimean-Congo hemorrhagic fever. In: Monath TP (ed.) The Arboviruses: Epidemiology and Ecology. Vol 2. Boca Raton, FL: CRC Press; 1988; 177-260
4. H.C.Maltezou, L.Andonova, R.Andraghetti, M.Bouloy, O.Ergonul, F.Jongejan, N.Kalvatchev, S.Nichol, M.Niedrig, A.Platonov, et al. Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness. Euro Surveill 2010; 15(10): p:19504; PMID:20403306
5. R.W.Sidwell, D.F.Smee. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res 2003; 57(1-2): p:101-11; PMID:12615306; http://dx.doi.org/10.1016/S0166-3542(02)00203-6
6. R.A.Zilinskas. Iraq's biological weapons. The past as future? Jama 1997; 278(5): p:418-24; PMID:9244334; http://dx.doi.org/10.1001/jama.1997.03550050080037
7. M.S.Bronze, M.M.Huycke, L.J.Machado, G.W.Voskuhl, R.A.Greenfield. Viral agents as biological weapons and agents of bioterrorism. Am J Med Sci 2002; 323(6): p:316-25; PMID:12074486; http://dx.doi.org/10.1097/00000441-200206000-00004
8. A.Papa, E.Papadimitriou, I.Christova. The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain. Scand J Infect Dis 2011; 43(3): p:225-9; PMID:21142621; http://dx.doi.org/10.3109/00365548.2010.540036
9. M.Mousavi-Jazi, H.Karlberg, A.Papa, I.Christova, A.Mirazimi. Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine 2012; 30(44): p:6225-9; PMID:22902680; http://dx.doi.org/10.1016/j.vaccine.2012.08.003
10. K.Spik, A.Shurtleff, A.K.McElroy, M.C.Guttieri, J.W.Hooper, C.SchmalJohn. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 2006; 24(21): p:4657-66; PMID:16174542; http://dx.doi.org/10.1016/j.vaccine.2005.08.034
11. S.M.Ghiasi, A.H.Salmanian, S.Chinikar, S.Zakeri. Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. Clin Vaccine Immunol 2011; 18(12): p:2031-7; PMID:22012978; http://dx.doi.org/10.1128/CVI.05352-11
12. K.R.Buttigieg, S.D.Dowall, S.Findlay-Wilson, A.Miloszewska, E.Rayner, R.Hewson, M.W.Carroll. A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model. PLoS One 2014; 9(3): p:e91516; PMID:24621656; http://dx.doi.org/10.1371/journal.pone.0091516
13. C.S.Schmaljohn, S.T.Nichol, Bunyaviridae, in Fields Virology, D.M.Knipe, P.M.Howley, Editors. Lippincott Williams & Wilkins: Philadelphia 2007. p:1741-1789
14. R.Hewson, J.Chamberlain, V.Mioulet, G.Lloyd, B.Jamil, R.Hasan, A.Gmyl, L.Gmyl, S.E.Smirnova, A.Lukashev, et al. Crimean-Congo haemorrhagic fever virus: sequence analysis of the small RNA segments from a collection of viruses world wide. Virus Res 2004; 102(2): p:185-9; PMID:15084400; http://dx.doi.org/10.1016/j.virusres.2003.12.035
15. P.Maes, J.Clement, M.Van Ranst. Recent approaches in hantavirus vaccine development. Expert Rev Vaccines 2009; 8(1): p:67-76; PMID:19093774; http://dx.doi.org/10.1586/14760584.8.1.67
16. H.Boshra, G.Lorenzo, F.Rodriguez, A.Brun. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(−/−) mice upon lethal virus challenge. Vaccine 2011; 29(27): p:4469-75; PMID:21549790; http://dx.doi.org/10.1016/j.vaccine.2011.04.043
17. S.D.Carter, R.Surtees, C.T.Walter, A.Ariza, É.Bergeron, S.T.Nichol, J.A.Hiscox, T.A.Edwards, J.N.Barr. Structure, function, and evolution of the Crimean-Congo hemorrhagic fever virus nucleocapsid protein. J Virol 2012; 86(20): p:10914-23; PMID:22875964; http://dx.doi.org/10.1128/JVI.01555-12
18. Y.Wang, S.Dutta, H.Karlberg, S.Devignot, F.Weber, Q.Hao, Y.J.Tan, A.Mirazimi, M.Kotaka. Structure of Crimean-Congo hemorrhagic fever virus nucleoprotein: superhelical homo-oligomers and the role of caspase-3 cleavage. J Virol 2012; 86(22): p:12294-303; PMID:22951837; http://dx.doi.org/10.1128/JVI.01627-12
19. H.Karlberg, Y.J.Tan, A.Mirazimi. Induction of caspase activation and cleavage of the viral nucleocapsid protein in different cell types during Crimean-Congo hemorrhagic fever virus infection. J Biol Chem 2011; 286(5): p:3227-34; PMID:21123175; http://dx.doi.org/10.1074/jbc.M110.149369
20. J.A.Wilson, M.K.Hart. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001; 75(6): p:2660-4; PMID:11222689; http://dx.doi.org/10.1128/JVI.75.6.2660-2664.2001
21. Y.Tsuda, P.Caposio, C.J.Parkins, S.Botto, I.Messaoudi, L.Cicin-Sain, H.Feldmann, M.A.Jarvis. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 2011; 5(8): p:e1275; PMID:21858240; http://dx.doi.org/10.1371/journal.pntd.0001275
22. X.Xu, S.L.Ruo, J.B.McCormick, S.P.Fisher-Hoch. Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am J Trop Med Hyg 1992; 47(4): p:397-404; PMID:1359802
23. S.L.Epstein, W.P.Kong, J.A.Misplon, C.Y.Lo, T.M.Tumpey, L.Xu, G.J.Nabel. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005; 23(46-47): p:5404-10; PMID:16011865; http://dx.doi.org/10.1016/j.vaccine.2005.04.047
24. A.Hashem, B.Jaentschke, C.Gravel, M.Tocchi, T.Doyle, M.Rosu-Myles, R.He, X.Li. Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge. Hum Vaccin Immunother 2012; 8(4): p:425-30; PMID:22370512; http://dx.doi.org/10.4161/hv.19109
25. J.C.Clegg, G.Lloyd. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet 1987; 2(8552): p. 186-8; PMID:2885642; http://dx.doi.org/10.1016/S0140-6736(87)90767-7
26. B.Bankamp, U.G.Brinckmann, A.Reich, S.Niewiesk, V.ter Meulen, U.G.Liebert. Measles virus nucleocapsid protein protects rats from encephalitis. J Virol 1991; 65(4): p:1695-700; PMID:1825854
27. D.Y.Ozols, W.E.Rawls, K.L.Rosenthal, D.G.Harnish. The nucleoprotein of Pichinde virus expressed by a vaccinia-Pichinde virus recombinant partially protects hamsters from lethal virus challenge. Arch Virol 1994; 139(1–2): p“23-36; PMID:7826212; http://dx.doi.org/10.1007/BF01309452
28. D.L.Lodmell, J.W.Sumner, J.J.Esposito, W.J.Bellini, L.C.Ewalt. Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection. J Virol 1991; 65(6): p:3400-5; PMID:2033678
29. A.C.Marriott, P.A.Nuttall. Comparison of the S RNA segments and nucleoprotein sequences of Crimean-Congo hemorrhagic fever, Hazara, and Dugbe viruses. Virology 1992; 189(2): p. 795-9; PMID:1641991; http://dx.doi.org/10.1016/0042-6822(92)90609-S
30. C.E.Gomez, J.L.Nájera, M.Krupa, B.Perdiguero, M.Esteban. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 2011; 11(3): p:189-217; PMID:21453284; http://dx.doi.org/10.2174/156652311795684731
31. C.S.Rollier, A.Reyes-Sandoval, M.G.Cottingham, K.Ewer, A.V.Hill. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011; 23(3): p:377-82; http://dx.doi.org/10.1016/j.coi.2011.03.006
32. K.Kolibab, A.Yang, S.C.Derrick, T.A.Waldmann, L.P.Perera, S.L.Morris. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol 2010; 17(5): p:793-801; PMID:20357059; http://dx.doi.org/10.1128/CVI.00006-10
33. S.Mehendale, M.Thakar, S.Sahay, M.Kumar, A.Shete, P.Sathyamurthi, A.Verma, S.Ke, A.Shrotri, J.Gilmour, et al. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers. PLoS One 2013; 8(2): p:e55831; PMID:23418465; http://dx.doi.org/10.1371/journal.pone.0055831
34. M.G.Cottingham, M.W.Carroll. Recombinant MVA vaccines: dispelling the myths. Vaccine 2013; 31(39): p:4247-51; PMID:23523407; http://dx.doi.org/10.1016/j.vaccine.2013.03.021
35. R.Harrop, W.Shingler, M.Kelleher, J.de Belin, P.Treasure. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J Immunother 2010; 33(9): p:999-1005; PMID:20948436; http://dx.doi.org/10.1097/CJI.0b013e3181f5dac7
36. P.A.Goepfert, M.L.Elizaga, A.Sato, L.Qin, M.Cardinali, C.M.Hay, J.Hural, S.C.DeRosa, O.D.DeFawe, G.D.Tomaras, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203(5): p:610-9; PMID:21282192; http://dx.doi.org/10.1093/infdis/jiq105
37. A.Bertolotti-Ciarlet, J.Smith, K.Strecker, J.Paragas, L.A.Altamura, J.M.McFalls, N.Frias-Stäheli, A.García-Sastre, C.S.Schmaljohn, R.W.Doms. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J Virol 2005; 79(10): p. 6152-61; PMID:15858000; http://dx.doi.org/10.1128/JVI.79.10.6152-6161.2005
38. N.K.Blackburn, T.G.Besselaar, A.J.Shepherd, R.Swanepoel. Preparation and use of monoclonal antibodies for identifying Crimean-Congo hemorrhagic fever virus. Am J Trop Med Hyg 1987; 37(2): p:392-7; PMID:3116871
39. D.A.Bente, J.B.Alimonti, W.J.Shieh, G.Camus, U.Ströher, S.Zaki, S.M.Jones. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol 2010; 84(21): p:11089-100; PMID:20739514; http://dx.doi.org/10.1128/JVI.01383-10
40. S.Bereczky, G.Lindegren, H.Karlberg, S.Akerström, J.Klingström, A.Mirazimi. Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J Gen Virol 2010; 91(Pt 6): p:1473-7; PMID:20164263; http://dx.doi.org/10.1099/vir.0.019034-0
41. S.Akira. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 1999; 17(3): p:138-46; PMID:10342556; http://dx.doi.org/10.1002/stem.170138
42. K.Schroder, P.J.Hertzog, T.Ravasi, D.A.Hume. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75(2): p:163-89; PMID:14525967; http://dx.doi.org/10.1189/jlb.0603252
43. G.C.Sen. Viruses and interferons. Annu Rev Microbiol 2001; 55: p:255-81; PMID:11544356; http://dx.doi.org/10.1146/annurev.micro.55.1.255
44. L.E.Yauch, T.R.Prestwood, M.M.May, M.M.Morar, R.M.Zellweger, B.Peters, A.Sette, S.Shresta. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 2010; 185(9): p:5405-16; PMID:20870934; http://dx.doi.org/10.4049/jimmunol.1001709
45. L.E.Yauch, R.M.Zellweger, M.F.Kotturi, A.Qutubuddin, J.Sidney, B.Peters, T.R.Prestwood, A.Sette, S.Shresta. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 182(8): p:4865-73; PMID:19342665; http://dx.doi.org/10.4049/jimmunol.0801974
46. S.Zompi, B.H.Santich, P.R.Beatty, E.Harris. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 2012; 188(1): p:404-16; PMID:22131327; http://dx.doi.org/10.4049/jimmunol.1102124
47. H.Chu, S.C.Das, J.F.Fuchs, M.Suresh, S.C.Weaver, D.T.Stinchcomb, C.D.Partidos, J.E.Osorio. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine 2013; 31(33): p:3353-60; PMID:23727003; http://dx.doi.org/10.1016/j.vaccine.2013.05.059
48. G.Ma, M.Eschbaumer, A.Said, B.Hoffmann, M.Beer, N.Osterrieder. An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS One 2012; 7(4): p:e34425; PMID:22511939; http://dx.doi.org/10.1371/journal.pone.0034425
49. N.Paran, Y.Suezer, S.Lustig, T.Israely, A.Schwantes, S.Melamed, L.Katz, T.Preuss, K.M.Hanschmann, U.Kalinke, et al. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis 2009; 199(1): p:39-48; PMID:19012492; http://dx.doi.org/10.1086/595565
50. J.Castillo-Olivares, E.Calvo-Pinilla, I.Casanova, K.Bachanek-Bankowska, R.Chiam, S.Maan, J.M.Nieto, J.Ortego, P.P.Mertens. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PLoS One 2011; 6(1): p:e16503; PMID:21298069; http://dx.doi.org/10.1371/journal.pone.0016503
51. E.Grant, C.Wu, K.F.Chan, S.Eckle, M.Bharadwaj, Q.M.Zou, K.Kedzierska, W.Chen. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Immunol Cell Biol 2013; 91(2): p;184-94; PMID:23399741; http://dx.doi.org/10.1038/icb.2012.78
52. D.M.Carragher, D.A.Kaminski, A.Moquin, L.Hartson, T.D.Randall. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008; 181(6): p:4168-76; PMID:18768874; http://dx.doi.org/10.4049/jimmunol.181.6.4168
53. J.W.Yewdell, E.Frank, W.Gerhard. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 1981; 126(5): p:1814-9; PMID:7217668
54. B.Zheng, Y.Zhang, H.He, E.Marinova, K.Switzer, D.Wansley, I.Mbawuike, S.Han. Rectification of age-associated deficiency in cytotoxic T cell response to influenza A virus by immunization with immune complexes. J Immunol 2007; 179(9): p:6153-9; PMID:17947690; http://dx.doi.org/10.4049/jimmunol.179.9.6153
55. S.Sambhara, A.Kurichh, R.Miranda, T.Tumpey, T.Rowe, M.Renshaw, R.Arpino, A.Tamane, A.Kandil, O.James, et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 2001; 211(2): p:143-53; PMID:11591118; http://dx.doi.org/10.1006/cimm.2001.1835
56. S.M.Vassilenko, T.L.Vassilev, L.G.Bozadjiev, I.L.Bineva, G.Z.Kazarov. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet 1990; 335(8692): p:791-2; PMID:1969533; http://dx.doi.org/10.1016/0140-6736(90)90906-L
57. D.A.Bente, N.L.Forrester, D.M.Watts, A.J.McAuley, C.A.Whitehouse, M.Bray. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res 2013; 100(1): p:159-89
58. Z.Y.Yang, W.P.Kong, Y.Huang, A.Roberts, B.R.Murphy, K.Subbarao, G.J.Nabel. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004; 428(6982): p:561-4; PMID:15024391; http://dx.doi.org/10.1038/nature02463
59. R.M.Zellweger, R.Miller, W.E.Eddy, L.J.White, R.E.Johnston, S.Shresta. Role of humoral vs. cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013; 9(10): p:e1003723; PMID:24204271; http://dx.doi.org/10.1371/journal.ppat.1003723
60. H.Bisht, A.Roberts, L.Vogel, A.Bukreyev, P.L.Collins, B.R.Murphy, K.Subbarao, B.Moss. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 2004; 101(17): p:6641-6; PMID:15096611; http://dx.doi.org/10.1073/pnas.0401939101
61. Z.Wang, J.Martinez, W.Zhou, C.La Rosa, T.Srivastava, A.Dasgupta, R.Rawal, Z.Li, W.J.Britt, D.Diamond. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 2010; 28(6): p:1547-57; PMID:19969118; http://dx.doi.org/10.1016/j.vaccine.2009.11.056
62. M.Luo, P.Tao, J.Li, S.Zhou, D.Guo, Z.Pan. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. J Virol Methods 2008; 154(1-2): p:121-7; PMID:18789973; http://dx.doi.org/10.1016/j.jviromet.2008.08.011
63. J.Vipond, R.Vipond, E.Allen-Vercoe, S.O.Clark, G.J.Hatch, K.E.Gooch, J.Bacon, T.Hampshire, H.Shuttleworth, N.P.Minton, et al. Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge. Vaccine 2006; 24(37-39): p:6340-50; PMID:16781800; http://dx.doi.org/10.1016/j.vaccine.2006.05.025
64. F.Katzen. Gateway((R)) recombinational cloning: a biological operating system. Expert Opin Drug Discov 2007 2(4): p. 571-89; PMID:23484762; http://dx.doi.org/10.1517/17460441.2.4.571
65. P.L.Earl, B.Moss, L.S.Wyatt, M.W.Carroll. Generation of recombinant vaccinia viruses. Curr Protoc Protein Sci 2001 Chapter 5: p. Unit5 13; PMID:18429179; http://www.ncbi.nlm.nih.gov/pubmed/18429179
66. P.L.Earl, N.Cooper, L.S.Wyatt, B.Moss, M.W.Carroll. Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Protein Sci 2001 Chapter 5: p. Unit5 12; PMID:18429178; http://www.ncbi.nlm.nih.gov/pubmed/18429178
67. S.Shimizu. Routes of Administration, in The Laboratory Mouse. H.J.Hedrich, G.Bullock, Editors. Elsevier. 2004:p:527-542.